Investigational Device Exemption (IDE)

What it is

Investigational Device Exemption (IDE) authorizes use of an unapproved/uncleared device in a U.S. clinical study to collect safety and effectiveness data. It sets rules for sponsor, investigator, IRB, labeling, monitoring, and reporting so research protects subjects and generates valid evidence (21 CFR 812; 21 CFR 50, 56; ISO 14155).

Regulatory framework

• Core rule: IDE regulation (21 CFR 812) governs significant risk (SR) and non-significant risk (NSR) studies, exemptions, submissions, and conduct.
• Human subject protection: IRB review and informed consent (21 CFR 56, 21 CFR 50); financial disclosure (21 CFR 54).
• Exemptions: Certain diagnostic, consumer preference, and noninvasive studies when criteria are met (21 CFR 812.2(c)).
• Labeling: “Investigational device. Limited by United States law to investigational use.” (21 CFR 812.5).
• Expanded access: Emergency/compassionate/single-patient, continued access, and treatment IDE pathways (e.g., 21 CFR 812.35, 812.36; with 21 CFR 50.23, 56.104 for emergency use conditions).

Key elements

• SR vs NSR determination: IRB makes the initial risk decision; SR studies require FDA-approved IDE, NSR studies proceed with IRB approval and are “abbreviated IDEs” under 21 CFR 812.2(b).
• Sponsor duties: Monitor, ensure compliance, maintain records, report UADEs and progress/withdrawals (21 CFR 812.40–812.150).
• Investigator duties: Obtain consent/IRB approval, follow the plan, control the device, maintain/submit records (21 CFR 812.100–812.110).
• Investigational plan: Objectives, protocol, risk analysis, monitoring, labeling, records/reports (21 CFR 812.25).
• Reporting: UADE 10-working-day sponsor reports to FDA, investigators, and IRBs; annual progress and final reports (21 CFR 812.150).

Process — how it works

• 1) Assess risk & exemptions: Decide if the study is SR, NSR, or exempt under 812.2(c); prepare the IRB risk memo.
• 2) Prepare IDE (if SR): Submit IDE to FDA with cover letter, investigational plan, prior investigations, manufacturing information, investigator agreements, and IRB info (21 CFR 812.20–812.25).
• 3) Secure approvals: Obtain IRB approval and informed consent; for SR, wait for FDA IDE approval before enrolling (21 CFR 812.42).
• 4) Conduct & monitor: Use required labeling, control device accountability, monitor sites, and keep complete records.
• 5) Report: File UADEs (10 days), deviations affecting safety, withdrawals, and annual reports; notify of study completion (21 CFR 812.150).
• 6) Close & archive: Submit final report; retain records per regulation and sponsor policy.

Common pitfalls

• Misclassifying SR vs NSR, leading to enrollment before FDA approval when one is required.
• Missing or weak risk analysis and monitoring plan in the investigational plan (21 CFR 812.25).
• Incomplete UADE reporting or late IRB/FDA notifications (21 CFR 812.150).
• Improper device accountability, storage, or labeling at sites (21 CFR 812.140, 812.5).
• Protocol changes implemented without prior IRB/FDA approval when required.

Quick checks / Tips

• Can you defend the SR/NSR or exempt rationale with citations to 21 CFR 812.2?
• Does the plan include monitoring, risk analysis, and stopping rules (812.25)?
• Is the IDE labeling exact and applied at every site (812.5)?
• Are UADE workflows set to meet the 10-day sponsor reporting clock (812.150)?
• Have you trained investigators on device control, consent, and documentation (812.100–812.110)?